These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18979098)

  • 21. Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.
    Kmieciak M; Toor A; Graham L; Bear HD; Manjili MH
    J Vis Exp; 2011 Jan; (47):. PubMed ID: 21304453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.
    Chen Y; Hu D; Eling DJ; Robbins J; Kipps TJ
    Cancer Res; 1998 May; 58(9):1965-71. PubMed ID: 9581840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors.
    Wang LX; Plautz GE
    Breast Cancer Res Treat; 2012 Jul; 134(1):61-70. PubMed ID: 22173696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.
    Tsukamoto H; Nishikata R; Senju S; Nishimura Y
    Cancer Immunol Res; 2013 Jul; 1(1):64-76. PubMed ID: 24777249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
    Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
    J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
    Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
    Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunosuppressive tumor environment is the major impediment to successful therapeutic vaccination in Neu transgenic mice.
    Burgents JE; Moran TP; West ML; Davis NL; Johnston RE; Serody JS
    J Immunother; 2010 Jun; 33(5):482-91. PubMed ID: 20463599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
    Greifenberg V; Ribechini E; Rössner S; Lutz MB
    Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo 4-1BB deficiency in myeloid cells enhances peripheral T cell proliferation by increasing IL-15.
    Choi BK; Kim YH; Lee DG; Oh HS; Kim KH; Park SH; Lee J; Vinay DS; Kwon BS
    J Immunol; 2015 Feb; 194(4):1580-90. PubMed ID: 25601928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.
    Hegde VL; Singh UP; Nagarkatti PS; Nagarkatti M
    J Immunol; 2015 Jun; 194(11):5211-22. PubMed ID: 25917103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
    Aqbi HF; Coleman C; Zarei M; Manjili SH; Graham L; Koblinski J; Guo C; Xie Y; Guruli G; Bear HD; Idowu MO; Habibi M; Wang XY; Manjili MH
    Breast Cancer Res; 2020 Oct; 22(1):116. PubMed ID: 33115528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.
    Weiss VL; Lee TH; Song H; Kouo TS; Black CM; Sgouros G; Jaffee EM; Armstrong TD
    PLoS One; 2012; 7(2):e31962. PubMed ID: 22359647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.